Metaplastic breast carcinomas are basal-like tumours

Histopathology

Volumn 49, Issue 1, 2006, Pages 10-21

  Reis Filho, J S ^a,b   Milanezi, F ^b,c   Steele, D ^a   Savage, K ^a   Simpson, P T ^d   Nesland, J M ^e   Pereira, E M ^f   Lakhani, S R ^d   Schmitt, F C ^c,g  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF OSLO   (Norway)

^f Laboratory of Clinical Pathology Salomão and Zoppi   (Brazil)

^g University of Porto   (Portugal)

Author keywords

Carcinosarcoma; Epidermal growth factor receptor (HER1); Immunohistochemistry; Myoepithelial; Sarcomatoid carcinoma

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P63;

ARTICLE; BREAST CARCINOMA; CARCINOSARCOMA; DNA MICROARRAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINDLE CELL CARCINOMA; SQUAMOUS CELL METAPLASIA;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MEMBRANE PROTEINS; METAPLASIA; NEOPLASMS, BASAL CELL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 33745653114     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02467.x     Document Type: Article

References (45)

1. van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002; 161; 1991-1996.
2. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
4. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
5. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
6. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 2003; 100; 10393-10398.
7. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
8. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 2005; 116; 340-350.
9. Fulford LG, Easton DF, Sofronis A et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinomas of the breast. Pathol. Int. 2004; 54; A2-A3 [Abstract].
10. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum. Pathol. 1989; 20; 732-740.
11. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989; 64; 1490-1499.
12. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum. Pathol. 1989; 20; 628-635.
13. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. V. Metaplastic carcinoma with osteoclastic giant cells. Hum. Pathol. 1990; 21; 1142-1150.
14. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990; 65; 272-276.
15. Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. NY State J. Med. 1973; 73; 1078-1082.
16. Oberman HA. Metaplastic carcinoma of the breast. A clinico-pathologic study of 29 patients. Am. J. Surg. Pathol. 1987; 11; 918-929.
17. Reis-Filho JS, Milanezi F, Silva P, Schmitt FC. Maspin expression in myoepithelial tumors of the breast. Pathol. Res. Pract. 2001; 197; 817-821.
18. Reis-Filho JS, Schmitt FC. p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology 2003; 42; 94-95.
19. Reis-Filho JS, Milanezi F, Paredes J et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl. Immunohistochem. Mol. Morph. 2003; 11; 1-8.
20. Simpson PT, Gale T, Reis-Filho JS et al. Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J. Pathol. 2004; 202; 274-285.
21. Popnikolov NK, Ayala AG, Graves K, Gatalica Z. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am. J. Clin. Pathol. 2003; 120; 161-167.
22. Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum. Pathol. 2003; 34; 1009-1015.
23. Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am. J. Surg. Pathol 2005; 29; 347-353.
24. Reis-Filho JS, Simpson PT, Jones C et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 2005; 207; 1-13.
25. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999; 17; 1983-1987.
26. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 2005; 11; 5175-5180.
27. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 2000; 24; 197-202.
28. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum. Pathol. 1999; 30; 1134-1139.
29. Jacquemier J, Padovani L, Rabayrol L et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol. 2005; 207; 260-268.
30. Sapino A, Papotti M, Sanfilippo B, Gugliotta P, Bussolati G. Tumor types derived from epithelial and myoepithelial cell lines of R3230AC rat mammary carcinoma. Cancer Res. 1992; 52; 1553-1560.
31. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am. J. Surg. Pathol. 2004; 28; 1506-1512.
32. Adem C, Reynolds C, Adlakha H, Roche PC, Nascimento AG. Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients. Histopathology 2002; 40; 556-562.
33. Raju GC. The histological and immunohistochemical evidence of squamous metaplasia from the myoepithelial cells in the breast. Histopathology 1990; 17; 272-275.
34. Reddick RL, Jennette JC, Askin FB. Squamous metaplasia of the breast. An ultrastructural and immunologic evaluation. Am. J. Clin. Pathol. 1985; 84; 530-533.
35. O'Hare MJ, Ormerod MG, Monaghan P, Lane EB, Gusterson BA. Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation 1991; 46; 209-221.
36. Enghardt MH, Hale JH. An epithelial and spindle cell breast tumour of myoepithelial origin. An immunohistochemical and ultrastructural study. Virchows Arch. A Pathol. Anat. Histopathol. 1989; 416; 177-184.
37. Harb JM, Komorowski RA, Vitali CM. Metaplastic breast carcinoma invading chest wall. Ultrastruct. Pathol. 1995; 19; 439-143.
38. Banerjee S, Reis-Filho JS, Ashley S et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006; DOI: 10.1136/jcp.2005.033043.
39. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11; 5678-5685.
40. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447; 688-694.
41. Jones C, Ford E, Gillett C et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin. Cancer Res. 2004; 10; 5988-5997.
42. Reis-Filho JS, Milanezi F, Carvalho S et al. Metaplastic breast carcinomas show EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridisation analysis. Breast Cancer Res. 2005; 7; R1028-1035.
43. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J. Clin. Pathol. 2005; 58; 700-704.
44. Barnes PJ, Boutilier R, Chiasson D, Rayson D. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res. Treat. 2005; 91; 173-178.
45. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 2005; 97; 643-655.